ArticleCancer management and research2021

Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.

Francesco Facchinetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.